Protective effect of vitamin E and atorvastatin against potassium dichromate-induced nephrotoxicity in rats  by Mehany, Hany A. et al.
ww.sciencedirect.com
b e n i - s u e f u n i v e r s i t y j o u r n a l o f b a s i c a n d a p p l i e d s c i e n c e s 2 ( 2 0 1 3 ) 9 6e1 0 2Available online at wScienceDirect
journal homepage: www.elsevier .com/locate/bjbasFull Length ArticleProtective effect of vitamin E and atorvastatin
against potassium dichromate-induced
nephrotoxicity in ratsHany A. Mehany b,*, Amira M. Abo-youssef b, Lamiaa A. Ahmed a,
El- Shaimaa A. Arafa b, Hekma A. Abd El-Latif c
aPharmacology and Toxicology Department, Faculty of Pharmacy, Cairo University, Egypt
b Pharmacology and Toxicology Department, Faculty of Pharmacy, Beni-Suef University, Egypt
cPharmacology and Toxicology Department, Faculty of Pharmacy, Umm Al-Qurah University, Saudi Arabiaa r t i c l e i n f o
Article history:
Received 10 January 2013
Accepted 25 February 2013
Available online 26 October 2013
Keywords:
Chromium (Cr)
Potassium dichromate
(Pot. dichromate)
Atorvastatin (ATO)
Vitamin E
Oxidative stress
Reactive oxygen species (ROS)* Corresponding author. Tel.: þ20 2 (0)11 422
E-mail address: hanyali28@yahoo.com (H
Peer review under the responsibility of Ben
Production and hosting by El
2314-8535/$ e see front matter Copyright 20
http://dx.doi.org/10.1016/j.bjbas.2013.02.002a b s t r a c t
Potassium dichromate, a Cr (VI) compound, is the most toxic form of Cr (VI) and has been
demonstrated to induce nephrotoxicity associated with oxidative stress in humans and
animals. The wide environmental distribution of Cr lead to an increased interest of its
toxicity and biological effects. The present study was designed to investigate the protective
effect of vitamin E and atorvastatin against potassium dichromate-induced nephrotoxicity
in rats. A single injection of potassium dichromate (15 mg/kg) to rats induced renal tubule
damage and an increase in the following markers of renal injury 2 days later; blood urea
nitrogen and serum creatinine. In addition, potassium dichromate injection increased the
following nitrosative and oxidative stress biomarkers in kidney; malondialdehyde (MDA),
total nitrate/nitrite (Nox). This was associated with a significant reduction in kidney
glutathione (GSH), metallothionein (MT) contents and superoxide dismutase (SOD) activity.
Furthermore inflammatory mediators such as myeloperoxidase (MPO) and tumor necrosis
alpha (TNF-a) were increased. Renal damaged was also evidenced by the change in the
kidney histopathological picture. Two weeks pre-treatment with vitamin E or atorvastatin
before dichromate administration markedly improved its toxicity as indicated by reduction
of serum urea and creatinine as well as improvement of kidney histopathological changes.
Oxidative stress biomarkers such as renal MDA and nitric oxide contents were also
decreased. Kidney superoxide dismutase activity was restored after pre-treatment with
vitamin E. Furthermore, atorvastatin significantly reduced TNF-a content and MPO activity
while vitamin E reduced TNF-a content. It could be concluded that the ability of vitamin E22773.
.A. Mehany).
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associated with their antioxidant and anti-inflammatory properties.
Copyright 2013, Beni-Suef University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction samples were collected and serum separated for estimation ofPotassium dichromate (K2Cr2O7) is a chemical compound
widely used inmetallurgy, chrome plating, chemical industry,
textile manufacture, wood preservation, photography and
photoengraving, refractory and stainless steel industries and
cooling systems (Barceloux, 1999). The oxidation state and
solubility of chromium (Cr) compounds determine their
toxicity. In contrast to Cr (III), which is a naturally occurring
form and an essential trace element for humans and others
mammals, Cr(VI) compounds are highly toxic (Wang et al.,
2006). Potassium dichromate is a hexavalent form of Cr and
has been demonstrated to induce oxidative stress and carci-
nogenic in nature (Stohs and Bagchi, 1995; Bagchi et al.,
2002a,b).
Vitamin E is a naturally occurring, potent lipid-soluble,
chain-breaking antioxidant that scavenges reactive oxygen
species and lipid peroxyl radicals both in vitro and vivo (Kir
et al., 2005; Arreola-Mendoza et al., 2006). It protects the
integrity of membrane by inhibiting lipid peroxidation and
augmenting the activity of antioxidant enzymes in the kidney
of diabetic rats (Kedziora-Kornatowaska et al., 2003) and is
also shown to suppress oxidative stress in rat remnant kidney
(Hahn et al., 1999).
Statins may exert lipid independent benefits against renal
injury in experimental states of chronic or acute renal function
impairment. Also statins, by reducing the synthesis of meval-
onateproducts, inhibit theactivationofRhoandRasguanosine
triphosphatases that may influence various signaling path-
ways involving renal inflammatory, proliferative, and cell-
death responses.Therefore, statins exert anti-inflammatory
actions in renal tissue. Renal antioxidant effects with conse-
quent endothelial function regulation of renal vasculature
following statin treatment may also account for pleiotropic
protection against renal injury (Kostapanous et al., 2009).
Therefore, the main goal of this study was to investigate
the protective effect of vitamin E and atorvastatin against
potassium dichromate induced renal damage.2. Materials & methods
2.1. Adult male Wistar rats used in this study were randomly
divided into 4 groups of eight animals each: The first group
received vehicle and served as normal control group; the
second group was subjected to a single s.c injection of potas-
siumdichromate (15mg/kg) to induce renal damage according
to the method of Biber et al. (1968). While the third and fourth
groups were pretreated with vitamin E (200 mg/kg) or ator-
vastatin (10 mg/kg) respectively for 14 days before potassium
dichromate and continued for 2 more days.
2.2. Forty eight hours after potassium dichromate admin-
istration animals were sacrificed by decapitation, bloodurea and creatinine. Kidneys were removed and homogenized
in ice-cold isotonic saline using (Ultra-Turrax T25, IKA
Labortechnik, Germany) for determination of oxidative stress
biomarkers and inflammatory mediators. In addition, histo-
logical examination of the kidneys was investigated.
2.3. Drugs & chemicals: Vitamin E capsules (200 mg) was
obtained from Farco pharmaceuticals andmixed with sesame
oil. Atorvastatin was obtained from E.P.I.C.O pharmaceuticals
and suspended in 0.5% carboxy methyl cellulose. Potassium
dichromate was purchased from Sisco Qualigens chemicals
(Mumbai, India).
2.4. Assay for GSH content was determined in kidney ho-
mogenate according to the method of Ahmed et al. (1991).
2.5. Assay forMDA contentwas carried out according to the
method of Uchiyama and Mihara (1978).
2.6. Assay for Kidney (MPO); extraction of MPO depends
upon procedures that disrupt the granules and render MPO
soluble in aqueous solution. This could be achieved by
freezing and rethawing followed by sonication in phosphate
buffer pH 6 containing 0.5% hexadecyl trimethyl ammonium
bromide HTAB (Bradley et al., 1982).
2.7. Assay for TNF-a was carried out using rat TNF-a
immunoassay kit (eBioscience, USA).
2.8. Assay for Kidney total Nitrate/Nitrite Content (NOx)
was determined as an index of nitric oxide (NO) content in
renal homogenate according to the method described by
Miranda et al. (2001).
2.9. Assay for metallothionein (MT) content in kidney was
assayed according to the method of Viarengo et al. (1997)
modified by Petrovic et al. (2001). The metallothionein con-
tent was evaluated using the colorimetric method with Ell-
man’s reagent.3. Statistical analysis
Results are expressed as mean  standard error (S.E.). The
statistical significance of differences between the experi-
mental groups was calculated by ANOVA followed by
TukeyeKramer tests. Analyses were performed using the
statistical software Graph Pad InStat. Results were considered
significant when P < 0.05.4. Results
As in Fig. 1(a & b), subcutaneous injection of a single dose of
potassium dichromate caused a significant elevation in serum
urea and creatinine. It was shown that vitamin E or atorvas-
tatin pre-treatment caused a significant reduction of the
elevated serum urea and creatinine levels.
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Fig. 1 e Effect of pre-treatment with vitamin E or atorvastatin on serum urea (a) and creatinine (b) levels following potassium
dichromate-induced nephrotoxicity in rats. Each value represents mean ± S.E of the mean. * Significantly different from
normal control group at p< 0.05. @ Significantly different from potassium dichromate group at p< 0.05. # Significantly
different from vitamin E treated group at p< 0.05.
normal control
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following potassium dichromate administration. Pre-
treatment with vitamin E as well as atorvastatin signifi-
cantly decreased the elevated renal MDA content.
Fig. 3 shows that the renal SOD activity was significantly
reduced following potassium dichromate administration and
the pre-treatment with vitamin E significantly restored the
renal SOD activity.
The reduction in renal GSH and MT content following po-
tassium dichromate administration is shown in Table 1.
Neither vitamin E nor atorvastatin significantly affected the
GSH and MT contents, although pre-treatment with vitamin E
normalized GSH.
Table 2 shows that potassium dichromate significantly
increased renal MPO activity as well as TNF-a and NOx con-
tents. Atorvastatin pre-treatment significantly reduced MPO
activity TNF-a and NOx contents. Pre-treatment with Vitamin
E significantly reduced the elevated TNF-a and NOx contents.
Fig. 4 shows that sections of normal kidneys (a) showing
the normal architecture of renal tissue, being composed of a
number of glomeruli embedded among a great number of
different tubules. Rats subjected to potassium dichromate (b)
showing coagulative necrosis of most of the convoluted tu-
bules at the cortex and the loss of the nuclei in the lining
epithelium of the necrotic tubules. Sections of kidneys of rats0
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Fig. 2 e Effect of pre-treatment with vitamin E or
atorvastatin on kidney malondialdehyde (MDA) content
following potassium dichromate-induced nephrotoxicity
in rats. Each value represents mean ± S.E of the mean.
* Significantly different from normal control group at
p< 0.05. @ Significantly different from potassium
dichromate group at p< 0.05. # Significantly different from
vitamin E treated group at p< 0.05.(c) pre-treated with vitamin E and subjected to potassium di-
chromate showing mild degeneration in the lining epithelium
of some tubules of the cortex. Sections of kidneys of rats (d)
pretreated with atorvastatin and subjected to potassium di-
chromate showing mild focal inflammatory cells infiltration
and focal hemorrhage in between the tubules at the cortex.5. Discussion
The kidney is the main route of Cr excretion, it has been re-
ported that acute exposure to potassium dichromate in rats
induced an increase in kidney Chromium content (Travacio
et al., 2001). Although chromium itself does not directly
generate free radicals, it indirectly generates various radicals
such as superoxide, nitrogen species like peroxynitrite, nitric
oxide and hydroxyl causing damage consistent with oxidative
stress (Pritchard et al., 2000).
Results of the present study showed marked increase in
serum creatinine and urea levels following potassium di-
chromate administration. In addition potassium dichromate
induced toxic injuries to the renal tubules and loss of func-
tional integrity in the kidney as seen by histopathologial0
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Fig. 3 e Effect of pre-treatment with vitamin E or
atorvastatin on kidney superoxide dismutase (SOD)
content following potassium dichromate-induced
nephrotoxicity in rats. Each value represents mean ± S.E of
the mean. * Significantly different from normal control
group at p< 0.05. @ Significantly different from potassium
dichromate group at p< 0.05. # Significantly different from
vitamin E treated group at p< 0.05.
Table 1 e Effect of pre-treatment with vitamin E or
atorvastatin on kidney glutathione (GSH) and
metallothionein (MT) contents following potassium
dichromate-induced nephrotoxicity in rats.
Treatments and
parameters
GSH
(mg/g wet tissue)
MT
(mg/g wet tissue)
Normal control 12.20  0.25 101.95  6.20
Pot. dichromate 10.9  0.24* 58.20  5.44*
Vitamin E þ Pot.
dichromate
11.92  0.23 45.57  2.92*
Atorvastatin þ Pot.
Dichromate
10.85  0.38* 47.37  3.00*
Each value represents mean  S.E of the mean.
*Significantly different from normal control value at p < 0.05.
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(Arreola-Mendoza et al., 2006). Previous study showed that
exposure to Cr (VI) compounds can lead to nephrotoxicity in
humans and experimental animals (Fatima et al., 2005). The
role of oxidative stress in dichromate-induced kidney damage
has been supported by the present work and previous studies
(Pedraza-Chaverri et al., 2008; Yam-canul et al., 2008). Inside
the cell, Cr (VI) is reduced to Cr (III). This reduction process
generates reactive oxygen species (ROS) and induces soft tis-
sues damage such as liver, pancreas, cerebellum and kidney
(Bagchi et al., 2002a,b; Fatima et al., 2005). Large amounts of
ROS generated by this process can bring on injury to cellular
proteins, lipids, and DNA leading to oxidative stress (Nordbeg
and Arner, 2001). The observed increase in MDA and NO is a
good evidence for this oxidative stress. Potassium dichromate
may lead to induction of inducible nitric oxide synthase,
resulting in an increased production of NO and formation of
toxic peroxynitrite (Coppo and Amore, 2000). Moreover an
enhancement of NO was reported by Bagchi et al. (1995) in
peritoneal cells from sodium dichromate-administered rats.
Furthermore potassium dichromate administration resulted
in the reduction of renal GSH content as compared to normal
control group which is in accordance with results obtained
before by Khan et al. (2010) and Molina-Jijo´n et al. (2012).
Glutathione is normally present in millimolar concentra-
tions in cells and is known to protect the cellular system
against the toxic effects of lipid peroxidation. It is very impor-
tant in maintaining cellular redox status (Rao and Shaha, 2001)
and its depletion is considered as a marker of oxidative stress
(Lu, 1999).
In the present study, administration of potassium dichro-
mate significantly decreased the renal metallothionein (MT)Table 2 e Effect of pre-treatment with vitamin E or atorvastati
contents following potassium dichromate-induced nephrotoxi
Treatments and parameters MPO (U/g wet tissue)
Normal control 0.44  0.02
Pot. dichromate 1.41  0.05*
Vitamin E þ Pot. dichromate 1.25  0.04*
Atorvastatin þ Pot. dichromate 1.15  0.10*@
Each value represents mean  S.E of the mean.
*Significantly different from normal control value at p < 0.05.
@ Significantly different from potassium dichromate group at p < 0.05.level. Metallothionein can’t bind Cr, but by scavenging ROS
(Thornally, 1985) it may act as a protective factor against Cr
(VI)-induced DNA lesions, reducing Cr (VI) directly to Cr (III).
Kimura et al. (2008) reported that Cr (VI) inhibited the ability of
MT to trans-activate its gene in response to zinc and that
potassium dichromate interfered with the capacity of MT to
form a co-activator complex containing histone acetyl trans-
ferase and recruiting RNA polymerase II to the promoter.
In addition administration of dichromate significantly
reduced renal SOD activity. The decreased SOD activity may
lead to massive production of superoxide anion. The produc-
tion of such anions overrides enzymatic activity and leads to a
fall in its concentration in renal tissue (Srinivasan et al., 2008).
Pedraza-chaverri et al. (2005) indicated that most of the anti-
oxidant enzymes become inactive after potassium dichro-
mate exposure either due to the direct binding of heavy
metals to enzyme active site if it contains SH group or to the
displacement of metal co-factors from active sites.
Another explanation of renal injury-induced by dichro-
mate is mediation of inflammatory process as seen by
increased pro-inflammatory cytokine renal TNF-a content
and MPO. This was shown previously by Wang et al. (2010)
who reported that hexavalent chromium could increase ROS
formation, activate the Akt, NF-kB, and MAPK pathways as
well as increase the production of cytokines, including TNF-a
and IL-1a. Furthermore, Gueniche et al. (1994) showed that
potassium dichromate could stimulate the release of cyto-
kines, such as TNF-a in normal human keratinocytes.
Pre-treatment with vitamin E significantly reduced the
elevated serum creatinine and urea levels and improved kid-
ney histopathological picture. These results prove that ob-
tained before by Khan et al. (2010) who showed the protective
role of tocotrienol against potassium dichromate-induced
nephrotoxicity. Moreover, Kagan et al. (1989) reported that
one of the ways in which a-tochopherol is believed to stabilize
membranes is to form a complex with the membrane lipids
components that have a tendency to destabilize the bilayer
structure thereby countering their effects and rendering the
membrane more stable as also supported by the observed
reduction of MDA and nitric oxide as well as increased
glutathione.
In addition, Halliwell and Gutteridge (2002) suggested that
treatment with a-tocopherol averted oxidative damage,
probably through its capacity to quickly and efficiently scav-
enge lipid peroxide radicals before they attack the membrane
lipids. This ability might be related to the fact that lipid per-
oxyl radicals react more rapidly (by four orders of magnitude)n on kidney myeloperoxide (MPO) activity, TNF-a and NOx
city in rats.
TNF-a (pg/gwet tissue) NOx (mmol/g wet tissue)
1484.24  40.33 140.52  13.38
2187.46  90.21* 269.74  8.98*
1744.79  51.84@ 202.04  14.48*@
1406.24  69.87@ 166.44  14.64@
Fig. 4 e (a) normal rat showing the normal architecture of renal tissue. (b) rats subjected to potassium dichromate showing
coagulative necrosis of most of the convoluted tubules at the cortex and the loss of the nuclei in the lining epithelium of the
necrotic tubules. Sections of kidneys of rats(c) pretreated with vitamin E and subjected to potassium dichromat showing
mild degeneration in the lining epithelium of some tubules of the cortex. (d) pretreated with atorvastatin and subjected to
potassium dichromate showing mild focal inflammatory cells infiltration and focal hemorrhage in between the tubules at
the cortex.
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pre-treatment with vitamin E significantly increased the renal
SOD activity.
Pre-treatment with vitamin E significantly reduced
dichromate-induced elevation in TNF-a. Vitamin E, in addition
to its direct antioxidant effects, may offer indirect protection
by decreasing neutrophil recruitment (Blesa et al., 2003;
Kolleck et al., 2002).
Moreover, Azzi et al. (2002) reported that a-tocopherol in-
hibits protein kinase C in various cell types, with the conse-
quent inhibition of platelet aggregation, nitric oxide
production in endothelial cells, and superoxide radical gen-
eration by neutrophils and macrophages.
In the current study, pre-treatmentwith atorvastatin (ATO)
reduced the elevated serum creatinine and urea levels
induced by potassium dichromate and improved kidney his-
topathological picture. Similarly Ozbek et al., (2009) reported a
protective effect of atorvastatin in gentamicin-induced
nephrotoxicity. Cuzzocrez et al. (2002) referred that protec-
tive role of atorvastatin could be attributed to its antioxidant
effect because it has been found that ROS may be involved in
the impairment of glomerular filtration rate. Antioxidant ef-
fect was also shown in this study where MDA and nitric oxide
were reduced.
Statins have been shown to reduce lipoprotein oxidation
and ameliorate free radical injury, and ATO possessessignificant antioxidant activity against OH and peroxyl radi-
cals. Furthermore, metabolites of ATO reduce lipoprotein
oxidation in a number of oxidative systems (Aviram et al.,
1989). Moreover, Iseri et al. (2007) reported that simvastatin
attenuated cisplatin-induced kidney damage via prevention
of lipid peroxidation. Previous studies demonstrated that
statins reduced ROS and superoxide anion renal production
either through down-regulation of NADPH oxidase activity or
by a decrease in the renal endothelial expression of inducible
NOS (Kostapanos et al., 2008; Yagiet al., 2008).
In the current study, pre-treatment with ATO significantly
reduced the elevated renal TNFa and MPO activity.
Inhibitionof increasedMPOactivitymay result indecreased
iNOS over expression and consequently lesser generation of
reactive oxygen and nitrogen species (Cuzzocrea et al., 2000).
There is emerging evidence to suggest that statins exert
anti-inflammatory effects by blocking the infiltration of in-
flammatory cells and down regulating the expression of in-
flammatory mediators, such as IL-6 and C-reactive protein
(Gueler et al., 2002; Sharyo et al., 2008).
Previous in vitro and in vivo results (Lopez et al., 2000;
Diomede et al., 2001) indicating that statins suppress the
synthesis of inflammatorymediators, such as TNF-a. Likewise
Mira et al. (2003) observed that simvastatin and cervistatin
decreased TNF-a and MPO through mevalonate-independent
pathways, but possibly by inhibiting the ERK pathway.
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